The estimated Net Worth of Gilles Gagnon is at least $228 mil dollars as of 9 October 2018. Gilles Gagnon owns over 10,000 units of Spectrum Pharmaceuticals stock worth over $74,675 and over the last 13 years Gilles sold SPPI stock worth over $153,300.
Gilles has made over 1 trades of the Spectrum Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently Gilles sold 10,000 units of SPPI stock worth $153,300 on 9 October 2018.
The largest trade Gilles's ever made was selling 10,000 units of Spectrum Pharmaceuticals stock on 9 October 2018 worth over $153,300. On average, Gilles trades about 1,250 units every 0 days since 2012. As of 9 October 2018 Gilles still owns at least 72,500 units of Spectrum Pharmaceuticals stock.
You can see the complete history of Gilles Gagnon stock trades at the bottom of the page.
Gilles's mailing address filed with the SEC is 11500 S. EASTERN AVE., SUITE 240, HENDERSON, NV, 89052.
Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen, eThomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.
spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include: